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Agitation is a common and urgent condition involving motor hyperactivity and symptoms such as irritability, 
combativeness, or impaired judgement. Rapid assessment and effective treatment are necessary to manage 
agitation and, potentially, to shorten the time to recovery. Rapid treatment with intramuscular (IM) typical an-
tipsychotics and/or benzodiazepines may be essential to prevent injury to the patients or others. However, IM 
typical antipsychotics are associated with acute extrapyramidal side effects, and IM benzodiazepines may cause 
excessive sedation leading to respiratory depression, ataxia, and confusion. Recently, an IM formulation of olan-
zapine may present several treatment advantages when rapid treatment of acute agitation is essential in patients 
with schizophrenia, bipolar disorder, and others. In addition, rapid initial dosing with olanzapine may be a useful 
approach to manage acute agitation in some patients with schizophrenia. (Korean J Psychopharmacol 2005;16 
(Supplement 1):71-76) 
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